ClinicalTrials.gg
CompletedNCT06474390Updated Oct 5, 2026

TipTraQ Home Sleep Test Validation Study, VGH

An observational study in Obstructive Sleep Apnea, sponsored by PranaQ Pte. Ltd.. Completed at 1 site in Taiwan. Open to participants aged 20 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by PranaQ Pte. Ltd. · Observational

How we know

Updated Oct 5, 2026Now CompletedPrimary completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
125
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 90 studies in Sleep Apnea, Obstructive with a site in Taiwan — 26 open to participants now, 27 under way, 3 of them phase 3. Sleep Apnea, Obstructive · Taiwan.

Enrollment
12th of 32
125 · median 103
Started
2024
with 7 others
Observational
32 of 90
7 open now
Registered
63rd of 90
by date
Lead sponsor
3 of 90
PranaQ Pte. Ltd.

Among the 90 studies in Sleep Apnea, Obstructive with a site in Taiwan, this one is the 12th largest by enrollment of the 32 observational ones that give a count, is one of 8 that started in 2024, is one of 32 observational ones, and was the 63rd registered.

Sleep Apnea, Obstructive

2,246 studies on the registry are indexed under Sleep Apnea, Obstructive; 476 are open to participants now.

Browse Sleep Apnea, Obstructive studies →

Open to participants now

26 of the 90 studies in Sleep Apnea, Obstructive with a site in Taiwan are open now. Recruiting first, the newest first:

21 more — sign in →

All 26 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 317 Sleep Apnea, Obstructive studies recruiting now, 149 (47%) set no upper age limit and 124 (39%) stop at 75 or younger; 53 take children under 18; 66 take healthy volunteers.

This study: 20 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 90 studies in Sleep Apnea, Obstructive with a site in Taiwan, or all of them as a file.
02

Study summary

A validation study has been designed to assess the performance of a home sleep test device, TipTraQ, for screening sleep apnea. The study involves participants wearing the TipTraQ device on their fingertip during a traditional sleep test, known as polysomnography (PSG), conducted in a sleep center. The performance of the device will then be evaluated by comparing the results from the TipTraQ system with those from the traditional sleep test.

Read the detailed description

This clinical study is designed to validate TipTraQ, a new sleep screening device developed by PranaQ, for the detection of Sleep Breathing Disorders (SBD), including obstructive sleep apnea-hypopnea syndrome (OSAHS). Given the high prevalence of undiagnosed OSAHS and the cumbersome nature of traditional polysomnography (PSG) - which involves multiple sensors and specialist interpretation - there is a pressing need for more accessible screening tools. TipTraQ aims to meet this need through a wearable device that utilizes photoplethysmography (PPG) and an accelerometer to monitor essential physiological parameters during sleep. This information is then analyzed by an interpretable artificial intelligence (AI) system to estimate key indicators of sleep health such as SpO2, total sleep time (TST), oxygen desaturation index (ODI), and apnea-hypopnea index (AHI).

The study is open-label and non-randomized, planning to recruit 125 subjects. Participants will use the TipTraQ device alongside a companion mobile app, with data analysis supported by AI technology hosted on a cloud server. The primary goal is to assess the accuracy of the TipTraQ system by comparing its output against the gold standard PSG annotations made by sleep experts.

This initiative represents a significant step towards simplifying and democratizing the screening process for sleep disorders, potentially enabling early detection and treatment for a larger segment of the population, thus mitigating personal health risks and broader societal impacts of undiagnosed SBD.

03

Conditions studied

  • Obstructive Sleep Apnea

Keywords

  • Obstructive Sleep Apnea
  • home sleep test
  • wearble device
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Healthy or people who has indication to conduct polysomnography (PSG).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects from the age of 20 and older that have an indication for an in-lab PSG study in the Duke University Hospital. The subject should be able to understand the study and sign the before being enrolled in the study. During the study period, the subject can withdraw from the study anytime.

Exclusion criteria

Exclusion Criteria:

Subjects with the following medical conditions will be excluded from this study:

  1. Heart transplant
  2. Heart failure, New Youk Heart Association () classification III or IV
  3. Chronic Obstructive Lung Disease, Global Initiative for Chronic Obstructive Lung Disease (GOLD) categorization 3 or 4
  4. Chronic opioid medication user Devastating Severe strokes, with the modified Rankin score (mRS)≥4
  5. Tracheostomy
  6. Incapable of comprehending and signing the and questionnaires, including but not limited to subjects with severe Alzheimers, unconscious by head trauma, or of someone with limited mental capacity Cannot correctly follow the order to use the TipTraQ device
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
125 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Oxygen Desaturation Index(ODI)

    Average desaturation episodes with a decrease in the oxygen saturation of ≥4% or 3% per hour

    Time frame: From the start of a single polysomnography study to the end of the recording. Time range from 4hour up to 10 hour.

  2. Apnea Hypopnea Index(AHI)

    The combined average number of apneas and hypopneas that occur per hour of sleep

    Time frame: From the start of a single polysomnography study to the end of the recording. Time range from 4hour up to 10 hour.

  3. Total Sleep Time(TST)

    Total sleep time during the polysomnography (PSG)

    Time frame: From the start of a single polysomnography study to the end of the recording. Time range from 4hour up to 10 hour.

07

Study locations

1 site
  • Taipei Veterans General Hospital
    Taipei, Taipei 201, Taiwan
08

References and documents

Individual participant data

Plan to share: No — The study collects mostly physiological signal data, not suitable for IPD

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2024 to primary completion in Apr 2026, 22 months.

Of 36 industry-sponsored observational studies under Sleep Apnea, Obstructive, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 93. This study's 22 months is above that.

Counting every sponsor, half of 294 studies reached it within 29 months; a quarter within 14 and three quarters within 63.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 5, 2026: primary completion May 2025 → Apr 2026 and completion May 2025 → Apr 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 13, 2024
First posted
Jun 25, 2024
StartActual
Jun 1, 2024
Primary completionActual
Apr 1, 2026was May 2025
CompletionActual
Apr 1, 2026was May 2025
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 5, 2026
Sites
1 site added, 1 site removed
Show site
  • Taipei Veterans General Hospital · Taipei, Taiwan
Show 1 removed
  • Taipei Veterans General Hospital · Taipei, Taiwan
Oct 5, 2026
Primary completion
May 31, 2025→Apr 1, 2026 (actual)
Oct 5, 2026
Study completion
May 31, 2025→Apr 1, 2026 (actual)
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    Recruiting→Completed
    1 site added, 1 site removed
    Show site
    • Taipei Veterans General Hospital · Taipei, Taiwan
    Show 1 removed
    • Taipei Veterans General Hospital · Taipei, Taiwan
    Primary completion May 31, 2025→Apr 1, 2026 (now actual)
    Study completion May 31, 2025→Apr 1, 2026 (now actual)
    + 5 other changes: identifiers, verification date, oversight details, contact details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06474390
Lead sponsor
PranaQ Pte. Ltd.
Responsible party
Sponsor
First posted
Jun 25, 2024
Start date
Jun 1, 2024
Primary completion
Apr 1, 2026
Completion
Apr 1, 2026
Last update
Oct 5, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion